CBT Stock Cabot (CBT, $101.07) RSI Indicator left the overbought zone on May 07, 2024

GET DAILY SIGNALS

Get AI intraday signals

CBT - Cabot Corp

RSI signal

View

Odds of DOWN Trend

Price: $101.07

Daily change: +$5.13 (+5.35%)

Daily volume: 767.3K

Capitalization: $5.6B

Industry: Chemicals: Specialty

CBT saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for CBT moved out of overbought territory on November 13, 2024. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 72 similar instances where the indicator exited the overbought zone. In of the 72 cases the stock moved lower. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CBT moved out of overbought territory on October 17, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CBT broke above its upper Bollinger Band on November 06, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2024. You may want to consider a long position or call options on CBT as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CBT just turned positive on November 06, 2024. Looking at past instances where CBT's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

CBT moved above its 50-day moving average on November 01, 2024 date and that indicates a change from a downward trend to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 259 cases where CBT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.868) is normal, around the industry mean (3.589). P/E Ratio (12.079) is within average values for comparable stocks, (33.984). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.035). Dividend Yield (0.017) settles around the average of (0.037) among similar stocks. P/S Ratio (1.330) is also within normal values, averaging (91.875).